Axsome Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system disorders for which there are limited treatment options.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Axsome Therapeutics news
02.05.2022
Axsome Therapeutics' GAAP loss for 3 months of 2022 was $39.632 million, up 35.5% from $29.259 million in the previous year.
axsometherapeuticsinc.gcs-web.com
01.03.2022
Axsome Therapeutics' GAAP loss for 2021 was $130.403 million, up 26.7% from $102.901 million the previous year.
08.11.2021
Axsome Therapeutics' GAAP loss for 9M 2021 was $96.427 million, up 30.8% from $73.736 million in the prior year.
09.08.2021
Axsome Therapeutics' GAAP loss for 6M 2021 was $61.544 million, up 21.1% from $50.811 million in the prior year.
General information
| Company name | Axsome Therapeutics |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038 (212) 332-3241 |
| Mailing address | 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038 |
| Website | www.axsome.com |
| Information disclosure | www.sec.gov |
English (US) 